Tth hormone supplementation on the clinical outcomes in patients with poor-quality embryo

The effect of growth hormone supplementation on the clinical outcomes in IVF patients with poor embryonic development

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900021992

Enrollment

Unknown

Registered

2019-03-19

Start date

2017-07-01

Completion date

Unknown

Last updated

2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

Group 1:Growth hormone supplement

Group 2:normal controlled ovarian stimulation

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged <45 years; 2. undergo cycle of IVF or ICSI; 3. Previous failure mainly because of low quality of oocyte (no grade I or II); 4. Normal ovulation and uterus.

Exclusion criteria

Exclusion criteria: 1. Endocrine diseases and endometriosis; 2. Mini-stimulation; 3. Natural assisted pregnancy. 4. PGD/PGS 5. Male factor; 6. Contraindication of growth hormone.

Design outcomes

Primary

Measure	Time frame
implantation rate;clinical pregnancy rate;number of oocytes retrieved;fertlization rate;number of transferable embryos;	—

Countries

China

Contacts

Public ContactHong Ye

Chongqing Health Center for Women and Children

cqtnljy@gmail.com+86 023-63839850

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026